General Nanotherapeutics

General Nanotherapeutics is a pre-clinical stage biotechnology company focused on developing targeted nanoparticles to treat and prevent immune-mediated and autoimmune diseases. Unlike standard broadly suppressive immunosuppressive therapies, the company's proprietary nanoparticles are designed to target specific immune cells in lymphoid tissue and reprogram them to restore immune tolerance. The platform utilizes nanoparticles (such as PLGA nanoparticles) coated with targeting moieties like anti-CD2 antibodies and loaded with tolerogenic cytokines, specifically Interleukin-2 (IL-2) and Transforming Growth Factor-beta (TGF-beta). This approach induces and expands protective CD4+ and CD8+ T regulatory cells (Tregs) and TGF-beta-producing regulatory natural killer (NK) cells, resetting the immune system to achieve long-term disease remission.